NasdaqGS:LMNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. More Details


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Luminex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LMNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

LMNX

1.1%

US Life Sciences

-0.8%

US Market


1 Year Return

4.9%

LMNX

49.8%

US Life Sciences

18.0%

US Market

Return vs Industry: LMNX underperformed the US Life Sciences industry which returned 45.1% over the past year.

Return vs Market: LMNX underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

LMNXIndustryMarket
7 Day-3.1%1.1%-0.8%
30 Day-15.4%12.8%6.8%
90 Day-40.0%13.1%8.9%
1 Year6.4%4.9%50.1%49.8%20.7%18.0%
3 Year8.4%4.6%99.0%97.7%41.5%32.1%
5 Year22.0%16.7%209.3%205.2%84.6%63.8%

Price Volatility Vs. Market

How volatile is Luminex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Luminex undervalued compared to its fair value and its price relative to the market?

1.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LMNX ($21.24) is trading below our estimate of fair value ($21.63)

Significantly Below Fair Value: LMNX is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: LMNX is poor value based on its PE Ratio (85x) compared to the US Life Sciences industry average (44.6x).

PE vs Market: LMNX is poor value based on its PE Ratio (85x) compared to the US market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: LMNX is poor value based on its PEG Ratio (9.3x)


Price to Book Ratio

PB vs Industry: LMNX is good value based on its PB Ratio (1.9x) compared to the US Life Sciences industry average (6.9x).


Next Steps

Future Growth

How is Luminex forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

9.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LMNX's forecast earnings growth (9.1% per year) is above the savings rate (2.2%).

Earnings vs Market: LMNX's earnings (9.1% per year) are forecast to grow slower than the US market (22% per year).

High Growth Earnings: LMNX's earnings are forecast to grow, but not significantly.

Revenue vs Market: LMNX's revenue (8.7% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: LMNX's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LMNX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Luminex performed over the past 5 years?

-38.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LMNX has high quality earnings.

Growing Profit Margin: LMNX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: LMNX's earnings have declined by 38.7% per year over the past 5 years.

Accelerating Growth: LMNX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: LMNX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (14.9%).


Return on Equity

High ROE: LMNX's Return on Equity (2.2%) is considered low.


Next Steps

Financial Health

How is Luminex's financial position?


Financial Position Analysis

Short Term Liabilities: LMNX's short term assets ($454.9M) exceed its short term liabilities ($62.8M).

Long Term Liabilities: LMNX's short term assets ($454.9M) exceed its long term liabilities ($217.1M).


Debt to Equity History and Analysis

Debt Level: LMNX's debt to equity ratio (39.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if LMNX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: LMNX's debt is not well covered by operating cash flow (19.6%).

Interest Coverage: LMNX's interest payments on its debt are well covered by EBIT (7.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Luminex current dividend yield, its reliability and sustainability?

1.69%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: LMNX's dividend (1.69%) is higher than the bottom 25% of dividend payers in the US market (1.65%).

High Dividend: LMNX's dividend (1.69%) is low compared to the top 25% of dividend payers in the US market (4.67%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, LMNX has been paying a dividend for less than 10 years.

Growing Dividend: LMNX's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (144.1%), LMNX's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Homi Shamir (66 yo)

6yrs

Tenure

US$3,362,135

Compensation

Mr. Nachum Shamir, also known as Homi, has been Chief Executive Officer and President of Luminex Corporation since October 15, 2014. Mr. Shamir served as Chief Executive Officer and President of Given at I ...


CEO Compensation Analysis

Compensation vs Market: Homi's total compensation ($USD3.36M) is about average for companies of similar size in the US market ($USD2.90M).

Compensation vs Earnings: Homi's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Nachum Shamir
Chairman6yrsUS$3.36m0.41%
$ 4.0m
Harriss Currie
CFO, Senior VP of Finance & Treasurer18yrsUS$1.11m0.54%
$ 5.3m
Richard Rew
Senior VP5.58yrsUS$909.31k0.072%
$ 704.2k
Todd Bennett
Senior Vice President of Global Sales & Customer Operations3.92yrsUS$900.02k0.12%
$ 1.1m
Randall Myers
Senior Vice President of Global Manufacturing & Quality5.58yrsUS$884.88k0.074%
$ 725.1k
Kendel Martin
Vice President of Accounting12.83yrsno datano data
Jeff Christensen
Senior Director of Investor Relationsno datano datano data
Eric Shapiro
Senior Vice President of Global Marketing5yrsno data0.073%
$ 719.4k
Nancy Fairchild
Senior Vice President of Human Resources5.75yrsUS$749.50k0.073%
$ 718.5k
Charles Collins
Senior Vice President of Research & Development2.75yrsno data0.075%
$ 733.9k

5.6yrs

Average Tenure

57yo

Average Age

Experienced Management: LMNX's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nachum Shamir
Chairman6yrsUS$3.36m0.41%
$ 4.0m
Jim Kever
Independent Director23.83yrsUS$178.98k0.35%
$ 3.4m
Kevin McNamara
Independent Director17.42yrsUS$198.94k0.072%
$ 710.8k
Edward Ogunro
Lead Independent Director0.17yrUS$178.98k0.13%
$ 1.3m
Thomas Erickson
Independent Director16.42yrsUS$178.93k0.19%
$ 1.9m
Dijuana Lewis
Independent Director1.08yrsUS$90.46k0.015%
$ 147.7k
Kenneth Samet
Independent Director1.83yrsUS$238.43k0.042%
$ 416.7k
Stephen Eck
Independent Director4.58yrsUS$148.97k0.072%
$ 705.4k

4.6yrs

Average Tenure

65.5yo

Average Age

Experienced Board: LMNX's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Luminex Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Luminex Corporation
  • Ticker: LMNX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$984.753m
  • Shares outstanding: 46.36m
  • Website: https://www.luminexcorp.com

Number of Employees


Location

  • Luminex Corporation
  • 12212 Technology Boulevard
  • Suite 130
  • Austin
  • Texas
  • 78727
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LMNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2000
LMXDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2000

Biography

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include L ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/23 00:53
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.